These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 39167870)
21. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations. Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742 [TBL] [Abstract][Full Text] [Related]
22. An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents. Rani I; Kaur N; Goyal A; Sharma M Anticancer Agents Med Chem; 2023; 23(5):525-561. PubMed ID: 35786337 [TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells. Shi X; Quan Y; Wang Y; Wang Y; Li Y Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409 [TBL] [Abstract][Full Text] [Related]
25. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations. Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040 [TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
27. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors. Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603 [TBL] [Abstract][Full Text] [Related]
28. Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety. Ke S; Shi L; Zhang Z; Yang Z Sci Rep; 2017 Mar; 7():44439. PubMed ID: 28290501 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors. Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J Eur J Med Chem; 2018 May; 151():836-848. PubMed ID: 29684894 [TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors. Wang NY; Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH Bioorg Med Chem Lett; 2020 Oct; 30(20):127479. PubMed ID: 32784091 [TBL] [Abstract][Full Text] [Related]
31. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives. Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930 [TBL] [Abstract][Full Text] [Related]
32. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421 [TBL] [Abstract][Full Text] [Related]
33. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937 [TBL] [Abstract][Full Text] [Related]
34. Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities. Akhtar MJ; Yar MS; Khan AA; Ali Z; Haider MR Mini Rev Med Chem; 2017; 17(17):1602-1632. PubMed ID: 27804888 [TBL] [Abstract][Full Text] [Related]
35. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold. Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417 [TBL] [Abstract][Full Text] [Related]
36. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556 [TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158 [TBL] [Abstract][Full Text] [Related]
38. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity. Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427 [TBL] [Abstract][Full Text] [Related]
39. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies. Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640 [TBL] [Abstract][Full Text] [Related]